Humoral immune responses against facultative pathogen Candida utilis in atopic patients with vulvovaginal candidiasis. Candida utilis glucomannan – New serologic biomarker

• Published in: Immunobiology (1979) Vol. 227; no. 1; p. 152154
• Main Authors: Paulovičová, E., Hrubiško, M.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier GmbH 01.01.2022
• Subjects: Antiglycan antibodies; Biomarkers; Candida; Candida albicans; Candida utilis; Candidiasis, Vulvovaginal - diagnosis; Female; Glucomannan; Humans; Immunity, Humoral; Immunoglobulin A; Immunoglobulin M; Mannans; Saccharomyces cerevisiae; Vulvovaginal candidiasis; Vulvovaginal candidiasis; Candida utilis; Antiglycan antibodies; Glucomannan
• ISSN: 0171-2985; 1878-3279; 1878-3279
• DOI: 10.1016/j.imbio.2021.152154

[Display omitted] Vulvovaginal candidiasis is one of the most commonly reported female genital tract infections, affecting approximately 70–75% of childbearing age women at least once during their lifetime. Approximately 50% of patients have refractory episodes and in 5–10% of cases the disease has a chronic course. The fungal cell wall represents the important host-invader interface. Cell-wall polysaccharides represent biological response modifiers and the pathogen-associated molecular patterns and virulence factors. Glycans are sensed by germ-line encoded pattern recognition receptors and reactively participate in immune system cell signaling. The most dominant cell-wall antigenic structures of Candida species as ß-glucan, α- and ß-mannans, glucomannan and other immunogenic polysaccharides are of particular relevancy for specific in vitro diagnosis and long-term follow-up of the Candida infection. In this study we assessed the immunobiological activity of facultative pathogen Candida utilis cell glucomannan and its effectivity as in vitro serological marker for antibody testing. The novel serologic assay has been developed and optimized for C. utilis serodiagnosis. The comparison assays were performed to establish relationship between antibodies against C. utilis, C. albicans and S. cerevisiae main cell-wall antigens in patient sera. The study evaluates applicability of glucomannan as serodiagnostic antigen and as a trigger of antigenspecific IgG, IgM and IgA antibody isotypes in the cohort of 35 atopic female subjects with recurrent vulvovaginal candidiasis. Statistically significant sera values of specific anti-glycan IgM and IgA class antibodies were revealed. The results are suggestive for efficient serological application of C.utilis glucomannan as in vitro disease marker and prospectively for follow-up of the specific long-term antimycotic therapy.